Results 61 to 70 of about 17,271 (194)

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki   +6 more
wiley   +1 more source

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley   +1 more source

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

open access: yesBJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics   +9 more
wiley   +1 more source

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone.

open access: yes, 2013
BACKGROUND: Abiraterone strongly inhibits androgen synthesis but may lead to an increase in mineralocorticoid hormones that may impair its long term tolerability in patients with prostate cancer.
Pia A   +16 more
core   +2 more sources

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial

open access: yesTrials, 2017
Background The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking.
Carsten-Henning Ohlmann   +6 more
doaj   +1 more source

ADAM19 Promotes EMT‐Related Changes and Serves as a Prognostic Marker in Circulating Tumor Cells of Renal Cell Carcinoma

open access: yesCancer Science, EarlyView.
ADAM19 is associated with EMT‐related malignant phenotypes and NOTCH/NF‐κB pathway activity in RCC and may serve as a prognostic biomarker in CTCs. ABSTRACT Detection of circulating tumor cells (CTCs), particularly characterization of their epithelial‐mesenchymal transition (EMT) phenotypes, may improve prognostic accuracy for malignancies ...
Minxin He   +8 more
wiley   +1 more source

Interleukin‐12: Central Roles in Immune Regulation and Disease Therapy

open access: yesImmunology &Cell Biology, EarlyView.
IL‐12 levels are tightly regulated to balance effective protective immunity against infections and cancer with the risk of excessive inflammation and autoimmune disease. Both insufficient and excessive IL‐12 activity can therefore be detrimental, highlighting the importance of precisely controlling its production and signaling. ABSTRACT Interleukin‐12 (
Anthi Psoma, Geert van den Bogaart
wiley   +1 more source

Prostatic Adenosquamous Carcinoma With a Minute Squamous Component in the Initial Biopsy and Early Liver Metastasis: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 6, November 2026.
ABSTRACT Introduction We report a case of de novo prostatic adenosquamous carcinoma with a minute squamous component in the initial biopsy and early liver metastasis despite a marked prostate‐specific antigen response. Case Presentation A 72‐year‐old man was diagnosed with locally advanced prostate cancer with nodal and multiple bone metastases ...
Yohei Tsubouchi   +9 more
wiley   +1 more source

Proteomic Analysis Reveals AMPKα‐Mediated Antiandrogen Resistance via Ferroptosis Suppression in Prostate Cancer

open access: yesCancer Science, Volume 117, Issue 11, Page 3086-3097, November 2026.
Antiandrogen‐resistant prostate cancer cells acquire ferroptosis resistance through AMPKα activation and upregulation of ferroptosis suppressor pathways. This adaptive state creates a therapeutic vulnerability, as GPX4 inhibition, particularly in combination with AMPKα inhibition, effectively suppresses the growth of resistant cells.
Masaki Shiota   +8 more
wiley   +1 more source

ASSESSING VIABILITY OF ENZALUTAMIDE IN CASTRATION-SAFE PROSTATE CANCER CASES ADVANCING AFTER DOCETAXEL AND ABIRATERONE

open access: yes, 2020
Intro: Abiraterone, an androgen blend inhibitor, was effectively utilized in cure of mutilation safe prostate malignant growth for 3 yr. Enzalutamide is the second-age nonsteroidal antiandrogen that has as of late been endorsed for identical sign ...
Dr Sarmad Khalil, Dr Saira Sarfraz, Dr Muhammad Younas
core   +1 more source

Home - About - Disclaimer - Privacy